Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 36, 2006 - Issue 12
Submit an article Journal homepage
106
Views
5
CrossRef citations to date
0
Altmetric
Original

Glucuronidation in the chimpanzee (Pan troglodytes): Studies with acetaminophen, oestradiol and morphine

H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
D. D. Christ Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
&
D. D. Christ Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
 show all
Pages 1178-1190 | Received 10 Jun 2006, Accepted 15 Jul 2006, Published online: 11 Aug 2009
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

The chimpanzee has recently been characterized as a surrogate for oxidative drug metabolism in humans and as a pharmacokinetic model for the selection of drug candidates. In the current study, the glucuronidation of acetaminophen, morphine and oestradiol was evaluated in the chimpanzee to extend the characterization of this important animal model. Following oral administration of acetaminophen (600 mg) to chimpanzees (n = 2), pharmacokinetics were comparable with previously reported human values, namely mean oral clearance 0.91 vs. 0.62 ± 0.05 l h−1 kg−1, apparent volume of distribution 2.29 vs. 1.65 ± 0.25 l kg−1, and half-life 1.86 vs. 1.89 ± 0.27 h, for chimpanzee vs. human, respectively. Urinary excretions (percentage of dose) of acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were also similar between chimpanzees and humans, namely 2.3 vs. 5.0, 63.1 vs. 54.7, and 25.0 vs. 32.3%, respectively. Acetaminophen, oestradiol and morphine glucuronide formation kinetics were investigated using chimpanzee (n = 2) and pooled human liver microsomes (n = 10). and (or ) for acetaminophen glucuronide, morphine 3- and 6-glucuronide, and oestradiol 3- and 17-glucuronide formation were comparable in both species. Eadie–Hofstee plots of oestradiol 3-glucuronide formation in chimpanzee microsomes were characteristic of autoactivation kinetics. Western immunoblot analysis of chimpanzee liver microsomes revealed a single immunoreactive band when probed with anti-human UGT1A1, anti-human UGT1A6, and anti-human UGT2B7. Taken collectively, these data demonstrate similar glucuronidation characteristics in chimpanzees and humans.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 897.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.